Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Raw Materials (2022 - 2025)

Historic Raw Materials for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $12.4 million.

  • Axsome Therapeutics' Raw Materials rose 6048.52% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year increase of 6048.52%. This contributed to the annual value of $9.5 million for FY2024, which is 7240.69% up from last year.
  • Latest data reveals that Axsome Therapeutics reported Raw Materials of $12.4 million as of Q3 2025, which was up 6048.52% from $11.7 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Raw Materials ranged from a high of $12.4 million in Q3 2025 and a low of $2.1 million during Q3 2022
  • Over the past 4 years, Axsome Therapeutics' median Raw Materials value was $5.6 million (recorded in 2024), while the average stood at $6.8 million.
  • As far as peak fluctuations go, Axsome Therapeutics' Raw Materials soared by 12377.68% in 2023, and later skyrocketed by 4590.85% in 2024.
  • Over the past 4 years, Axsome Therapeutics' Raw Materials (Quarter) stood at $2.5 million in 2022, then soared by 123.78% to $5.5 million in 2023, then surged by 72.41% to $9.5 million in 2024, then soared by 30.34% to $12.4 million in 2025.
  • Its last three reported values are $12.4 million in Q3 2025, $11.7 million for Q2 2025, and $11.5 million during Q1 2025.